文献速递膀胱癌与上尿路尿路上皮癌

经尿道膀胱肿瘤切除术后即刻热灌注化疗(I-HIVEC)的安全性与疗效

Safety and Efficacy of Immediate Hyperthermic Intravesical Chemotherapy Following Transurethral Resection of Bladder Tumour (I-HIVEC).
PubMed 文献 · Eur Urol Oncol · 2024-05-27

该先导研究评估非肌层浸润性膀胱癌患者经尿道膀胱肿瘤切除术(TURBT)后即刻使用传导式热灌注化疗系统(Combat BRS)灌注丝裂霉素C(MMC)的安全性。29例患者中术后额外并发症少,79.3%住院1天后出院,无患者需膀胱冲洗,发生6例I-II级不良事件(20.7%)和1例III级事件(3.4%)。3个月内无复发,12个月复发率为4.5%。

要点

  • TURBT后即刻HIVEC灌注MMC在29例患者中显示安全性可接受。
  • 79.3%患者住院1天后出院,无患者需膀胱冲洗。
  • 12个月复发率4.5%,3个月内无复发。

核心结论

  • TURBT后即刻HIVEC灌注MMC是安全的,但需进一步研究以对比标准冷灌注MMC评估长期疗效。

研究设计与样本

  • 先导研究,纳入拟行TURBT的乳头状膀胱肿瘤患者,29例接受HIVEC治疗。

主要发现

  • 29例接受HIVEC治疗的患者中,术后额外并发症少,79.3%住院1天后出院,无患者需膀胱冲洗。
  • 发生6例I-II级不良事件(20.7%)和1例III级事件(3.4%)。
  • 3个月内无复发,12个月复发率为4.5%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文指出需要更多患者和更长随访的进一步试验来确认结果。
  • 原文指出需要进一步研究以对比标准冷灌注MMC评估长期疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The recurrence rate following endoscopic treatment of non-muscle-invasive bladder cancer (NMIBC) remains high. Standard treatment includes intravesical instillation of chemotoxic agents such as mitomycin C (MMC) to reduce recurrence. It is postulated that upfront administration of hyperthermic intravesical MMC (HIVEC) immediately after transurethral resection of bladder tumour (TURBT) may enhance its efficacy, but evidence from human trials is scant. This pilot study explored the safety of immediate intravesical MMC instillation following TURBT using a conductive HIVEC system (Combat BRS). Patients diagnosed with papillary bladder tumours scheduled for TURBT were recruited. Among 29 patients treated with HIVEC, there was minimal additional postoperative morbidity. The majority (79.3%) were discharged after a hospital stay of 1 d, and no patient required bladder irrigation. There were six grade I-II adverse events (20.7%) and one grade III event (3.4%). No recurrences were observed within 3 mo, and the 12-mo recurrence rate was 4.5%. The study findings demonstrate that immediate HIVEC MMC instillation following TURBT is safe. Further research is needed to assess long-term efficacy in comparison to standard cold MMC. PATIENT SUMMARY: Non-muscle-invasive bladder cancer is treated with tumour removal via a telescope inserted into the bladder through the urethra (called TURBT). We tested the safety of treating the bladder with a warm solution of a chemotherapy drug (mitomycin C) immediately after TURBT, as this may prevent tumour recurrence. The treatment was safe and well tolerated. Further trials are needed with more patients and longer follow-up to confirm the results.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Wong CH, Ko IC, Leung DK, et al. Safety and Efficacy of Immediate Hyperthermic Intravesical Chemotherapy Following Transurethral Resection of Bladder Tumour (I-HIVEC). Eur Urol Oncol. 2024. PMID: 38806344. doi:10.1016/j.euo.2024.05.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。